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Nuclear transplantation experiments by
John Gurdon in amphibians established
that the genome of a differentiated cell
remains constant and can be reprog-
rammed into an embryonic state that
supports development of an entire
organism. The subsequent discovery of
induced pluripotent stem cells (iPSCs)
by Takahashi and Yamanaka provided
a molecular logic of how to achieve
cellular reprogramming in a culture dish
with defined factors.
Although iPSCsaremostlydiscussedas
tools fordiseasemodelingandcell therapy
these days, iPSC technology is an equally
valuable tool to revisit some of the funda-
mental questions of cell fate determination
raised by Gurdon’s seminal experiments.
How do reprogramming factors reverse
normal development?Whichmechanisms
normally prevent reprogramming in vivo
and are the same molecules involved in
cancer? How do transcription factors
remodel theepigenomeof acell?Are there
differences in the reprogramming process
between induced pluripotency, nuclear
transfer, and cellular fusion?
I am convinced that studying these
questions can teach us valuable lessons
about the principles of mammalian devel-
opment and the mechanisms that nor-
mally prevent cells from undergoing
malignant transformation. This research
might ultimately allow generation of any
desired cell state from existing cell types
by pushing a few defined molecular
switches. Similarly, this approach might
aid in the development of drugs that
prevent the corruption of these processes
in cancer.740 Cell Stem Cell 11, December 7, 2012 ª2Beginning of Chapter II
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Fifty years of effort in reprogramming
science have opened new doors for
regenerative medicine and disease
modeling with successful cell fate conver-
sion to pluripotency. With complementary
approaches for differentiation of pluripo-
tent stem cells (PSCs), we can now
generate various types of functional
differentiated cell types. Both approaches
have progressed tremendously in recent
years, and have now encountered
a common technological obstacle: the
immature phenotype of PSC-derived
cells. For many applications, particularly
for late-onset disease modeling and cell
transplantation therapies, there is
a desperate need for obtaining mature
cells. Although some evidence suggests
that physical stress, additional growth
factors, or prolonged culture can accel-
erate maturation or aging, these are not
fundamental solutions. Of note, recent
advances in direct lineage reprogram-
ming may possibly allow us to skip
directly to the end of differentiation for
any somatic cell type using suitable
combinations of transcription factors.
In the next decade, clinical studies with
iPSCs are likely to be conducted in some
nations, including Japan. Although the
need for evaluation varies circumstan-
tially, cell lines for clinical use should
always be top quality. Unlike in the past,
we are now able to easily detect details
such as single nucleotide variation in
iPSC genomes. Thus, a key issue remain-
ing may be to decide, ‘‘How strict or how
flexible should we be?’’012 Elsevier Inc.Genomic Considerations
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Cellular reprogramming has been recog-
nized for its potential as a tool for person-
alized medicine. Despite the remarkable
finding that transcription factors can
induce various cell fate changes in
a culture dish, insight into why a particular
factor can drive a given process remains
mysterious, and the interactions of
proteins and genomic elements that are
required for cell fate changes are often
unclear. The advent of powerful DNA
sequencing technologies now enables
high-resolution whole-genome analyses,
giving an unprecedented view of regula-
tory genomic elements. Integrating the
temporal dynamics of reprogramming
factor binding with genomic features
should guide our understanding of the
effective regulatory architecture of cell
fate changes during reprogramming and
help to identify the unknown events that
represent successful and unsuccessful
reprogramming. Why do certain cells
become pluripotent while the majority do
not? What accounts for the preceding
latency period? Due to the cellular hetero-
geneity of reprogramming, new technolo-
gies will need to be developed that allow
the isolation of faithful reprogramming
intermediates in which chromatin
engagement by the reprogramming
factors can be measured, ideally at the
single-cell level. Similarly, monitoring
how key cellular components are regu-
lated dynamically at the single-cell level
during reprogramming will enable us to
discover new phenomena of cell fate
changes concealed by conventional pop-
ulation studies.
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Regardless of whether reprogramming is
mediated by enucleated eggs or tran-
scription factors, the ability to dramati-
cally turn back the developmental clock
is one of the most fascinating topics in
biology. In the context of Waddington’s
terrain, John Gurdon and Shinya Yama-
naka are two of the most prominent navi-
gators who discovered the means to
connect somatic and pluripotent cell
states. Now that it is possible to recreate
the pluripotent states in vitro, we can start
to ask a new set of questions. How many
different cellular states can be created?
What are the codes for programming
each induced cellular state? Although
these cellular states may be artificial,
they provide unprecedented opportuni-
ties for unlocking new cellular potentials.
In my mind, the next big question will be
whether we can eventually build a guide-
book for systematically navigating
between different cellular states. From
there, we may be able to progressively
create an environment that is permissive
for different cellular states to coexist as
an entity with biological functions. The
lessons learned from stabilizing pluripo-
tent states emphasize the importance of
both intrinsic and extrinsic cellular
controls. As we develop a more compre-
hensive understanding of cells, the pros-
pect of writing this manual to navigate
with ease from one state to another may
not be a too distant one.A Game Changer for Infertility
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Many barriers to human embryonic stem
cell (hESC) research were lifted 5 years
agowith the generation of human induced
pluripotent stem cells (hiPSCs). In our
research program, the ability to differen-
tiate gametes genetically related to the
donor is of critical importance to under-
standing the genetic origins of human
infertility. Furthermore, hiPSC technology
could be a game changer for the treat-
ment of couples that suffer from nonge-
netic forms of infertility, permitting the
generation of replacement gametes from
hiPSCs.More than any other in vitro deriv-
ative, hiPSCs provide a compelling
advantage over hESCs to treat infertility,
as the hiPSC-derived gametes will be
genetically related to the donor parent.
Remarkably, in the last 2 years murine
iPSCs have been used to create func-
tional gametes following differentiation.
These experiments provide critical
proof-of-concept that hiPSCs could be
used to create human gametes that
support the birth of healthy individuals.
Moving forward, the creation of
nonhuman primate iPSC resources and
models are critical to proving that iPSC-
derived gametes are functional, and
therefore relevant biological models not
only for basic research, but also as
a safe treatment option for infertile
couples that consent to use this tech-
nology in the future.Cell Stem Cell 11,New Muscle for Old Hearts
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For more than a decade, the unfulfilled
promise of using adult stem cells for the
treatment of heart failure, a major cause
of death worldwide, has been a disap-
pointment. A large part of the problem is
that billions of cardiomyocytes (CMs) are
lost aftermyocardial infarction and neither
the various types of exogenous stem cells
that have been applied nor cardiac stem
cells are able to compensate for this
loss. Patient-derived iPSCs, with their
almost unlimited expansion capacity and
the potential to form functional CMs,
now provide a cell source that meets the
basic requirements of a technically
demanding but potentially more prom-
ising therapeutic concept: the repair of
injured or malformed myocardium
through implantation of in vitro engi-
neered heart muscle. Remarkably, robust
cardiac differentiation and enrichment
protocols have already been developed,
and novel technologies are available for
clinically safe transgenesis of iPSCs.
Of course, a number of unsolved
hurdles remain, including the need for
proper vascularization and the appear-
ance of genetic abnormalities in culture-
expanded iPSCs. The generally extremely
low incidence of CM-derived tumors,
however, argues for a low risk factor for
malignant transformation of terminally
differentiated iPSC-derived CMs, and
potential implant-related arrhythmias
could be controlled through artificial
pacemakers. Engineered myocardium
may therefore be among the first clinically
applied iPSC-based transplants.December 7, 2012 ª2012 Elsevier Inc. 741
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The ability to directly reprogram somatic
cells into iPSCs has stimulated strong
scientific interest in the regulatory mecha-
nisms that underlie the reprogramming
process. A major goal is to devise an
accurate picture of the temporal regula-
tion between transcription factors, chro-
matin remodelers, and global epigenetic
transitions that occurs during cellular re-
programming. However, the inefficiency
and inherent stochasticity of current re-
programming methods, together with the
inability to prospectively isolate the rare
cells that correctly reprogram into iPSCs,
limit our ability to address this question.
New approaches that allow single-cell
chromatin analysis are likely to lead to
a dramatic improvement. The field will
need to develop deterministic direct
approaches for reprogramming to iPSCs
and other state changes, such as robust
derivation of PGCs from ESCs. With
such tools in place, we will be able to
achieve a comprehensive understanding
of the consequences of introducing
defined factors on both chromatin remod-
eling and transcriptional programs that
drive transitions between cell states.
Collectively, the comparative analysis
and application of various experimental
platforms across different species will
provide a holistic and mechanistic under-
standing of how changes in chromatin
organization are translated into distinct
cellular states.742 Cell Stem Cell 11, December 7, 2012 ª2Next Stop: In Vivo and Direct
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The generation of iPSCs from somatic
cells, which demonstrated that cell fate
could be manipulated by simply intro-
ducing a few key factors, is amajor break-
through in developmental biology. This
conceptual revolution has inspired
researchers to engineer various function-
ally desirable cell types by direct lineage
reprogramming in vitro. Looking to the
future, I think in vivo direct reprogramming
will revolutionize regenerative medicine
and cell therapy in the coming decades.
Direct lineage reprogramming, in prin-
ciple, is more suitable and promising for
in vivo applications in regenerative medi-
cine because it bypasses the risk of
tumors posed by residual pluripotent cells
found in iPSC techniques. Moreover,
in vivo reprogramming avoids the risks
of genetic mutations arising from long-
term in vitro cell culture and difficulties in
transplantation. To achieve this goal,
however, we will need to overcome
some major hurdles. First, nonintegrative
and targeted delivery methods should be
established to deliver reprogramming
factors to appropriate sites in vivo.
Second, off-target effects should be
reduced to prevent the generation of
partially converted or transformed cells.
Third, reprogramming efficiency and
quality control should be improved to
meet the needs of in vivo applications. If
these hurdles are overcome, I anticipate
that in vivo reprogramming will become
a powerful tool not only for treating
disease but also for rejuvenating aged
tissue.012 Elsevier Inc.Deciphering Reprogramming
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John Gurdon’s experiments using frog
eggs revealed that the epigenome of
differentiated cells can be reset to give
rise to a viable fertile animal. However,
as cloning proved to be inefficient, the
understanding of the biology of this
process stalled for over 4 decades. Every-
thing changed with Yamanaka’s break-
through discovery showing that differenti-
ated cells can be directly induced to
pluripotency by defined factors, bypass-
ing the need for eggs. The great challenge
for the next 10 years is now to place the
pieces of the puzzle of biology of induced
pluripotency in the frame provided by Ya-
manaka’s work. Why is this important?
One cannot be naive and has to recognize
that we are still far from achieving an
optimal mammalian pluripotent cell, that
is, one that differentiates in an unbiased,
reproducible, and robust manner into
cells of all three germ layers. This problem
is particularly exemplified by human
PSCs. We need a better understanding
of the cell state transition leading to the
generation of the iPSC. This, combined
with studies on the biology of ESCs, will
provide us with the necessary robust
mechanistic insight to tackle the creation
of a much improved mammalian pluripo-
tent cell. Then we will be in a position to
deliver the much anticipated promise of
using human iPSCs as a platform for
large-scale applications in regenerative
medicine.
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Comprehensive sequencing of the human
genome was a revolutionary advance in
biology. iPSCs have arisen in the midst
of this Genomic Age, with disease models
and designer DNA modification assuming
central roles in human functional geno-
mics. Application of site-specific nucle-
ases and homologous recombination in
iPSCs may eventually render the human
genome as malleable as mouse ESCs.
With these tools, the reality of gene
correction for autologous cellular thera-
pies should materialize.
Importantly, patient-specific iPSCs
enable personal medicine paradigms
that demand strict validation. Although
genetic abnormalities have been
observed in iPSCs, the major contributors
remain unclear. Do mutations exist in the
somatic cell source or arise during re-
programming? Are they primarily the
result of extended in vitro culture? How
severely will off-target nuclease activity
exacerbate matters? Maintaining
genomic integrity is a fundamental
prerequisite for clinical iPSC applications.
So, how should we respond to the accu-
mulation of genetic grunge? Essentially:
screening and avoidance. Genomic rese-
quencing with inexpensive bench-top
technologies will eventually be common-
place. Parallel comparison of multiple
iPSC clones will mask phenotype-altering
genetic noise. Mechanisms that preserve
genomic integrity in the germline may
reveal biological checkpoints that may
be activated in iPSCs. For safe applica-
tion, prevention must accompany detec-
tion. Photo: Camilla Widebeck.Rewiring Cell Fate
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Two truly original studies separated by 50
years in history and science demon-
strated that the diversity of cell types
generated during development and differ-
entiation maintain remarkable plasticity.
While the approaches used in each case
were quite different, requiring either
nuclear transplantation or the addition of
exogenous factors, both involved rewiring
the regulatory circuitry of one cell type to
another. Arguably, reprogramming has
led to a new frontier in medicine providing
the possibility of using patient-specific
cells for replacement of diseased or aging
cells; however, these studies have also
opened up tremendous opportunities for
studying fundamental questions in
biology. For example, how is phenotype
stability normally buffered in the face of
changing developmental and environ-
mental landscapes? Similarly, can we
use the operational principles derived
from reprogramming to understand
cancer where loss of cell identity is a key
hallmark of tumor formation? Further-
more, why are some multicellular animals
able to regenerate tissues whereas
mammals have a limited capacity to do
so? Looking ahead, the remarkably
different reprogramming strategies used
to achieve transitions in cell fate suggest
that we may ultimately be able to use the
principles derived from these discoveries
to repurpose cells toward emergent
behaviors, opening a new era of synthetic
biology.Cell Stem Cell 11,Unlimited Reprogramming
Marius Wernig
Stanford University
These are exciting times for us
researchers working in the field of epige-
netic reprogramming. Just a few years
ago, the idea that unrelated cell types
could easily be converted into each other
was a fantasy. Now we have our hands at
the key control switches of cell identities
in a world where everything seems
possible. Not only have we learned how
to instill pluripotency in somatic cells, we
have also converted skin fibroblasts
directly into neurons, heart, blood,
muscle, and liver cells. We have coaxed
liver cells to neurons, and pancreas back
to liver. The effects are surprisingly simple
to accomplish, and hence remarkably
robust. Our ability to generate any cell
type from any other, as long as they can
be maintained in culture, appears to be
within reach. At the same time, we are
only beginning to understand how the
epigenetic barriers selected by evolution
to ensure physiologic stability are so
easy to overcome and how to utilize re-
programming for other things. There is
no doubt that reprogrammingwill become
a standard tool to study complex
diseases, especially when human cells
are not otherwise available. We may
even use such cells for autologous thera-
peutic grafts. But the story does not end in
the culture dish. Most fascinating are the
prospects for redirecting or even
completely switching a cell type’s identity
within the human body and thus effec-
tively interfering with disease processes.
I predict almost every medical discipline
will be enhanced by these applications.December 7, 2012 ª2012 Elsevier Inc. 743
